Skip to main content
. 2023 May 4;30(7):1726–1741. doi: 10.1038/s41418-023-01174-5

Fig. 1. Expression and localization of KCTD13 in the brain tissues of mice and patients with TLE.

Fig. 1

A, B Representative immunoblots (A) and quantification (B) of KCTD13 protein expression in mice hippocampal lysates at different time points after KA-induced SE compared to that in the sham control. n = 6 mice/group/time point, *p < 0.05, **p < 0.01, unpaired two-tailed Student’s t-test. C, D Representative immunoblots (C) and quantification (D) of KCTD13 protein expression in the temporal lobe of TLE patients compared with that of the control TBI group. n = 12/group, ***p < 0.001, unpaired two-tailed Student’s t-test. E Immunofluorescent labeling of KCTD13 and microtubule-associated protein 2 (MAP2) in cultured primary neurons. F Representative confocal images of KCTD13, MAP2, and glial fibrillary acidic protein (GFAP) immunofluorescence in the brain tissue samples from patients with TLE. G, H Representative confocal images of KCTD13, DAPI, NeuN, and GFAP immunofluorescence in hippocampus from KA epilepsy model mice. I Representative confocal images of colocalization of endogenously expressed KCTD13 with PSD95 and gephyrin in primary neurons.